Clinical Trial Update: Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating bevacizumab and cetuximab, with or without irinotecan, in irinotecan-refractory metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Cetuximab (Erbitux) (Cetuximab)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Status: COMPLETED